Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumab - Genova, Carlo; Marconi, Silvia; Chiorino, Giovanna; Guana, Francesca; Ostano, Paola; Santamaria, Sara; Rossi, Giovanni; Vanni, Irene; Longo, Luca; Tagliamento, Marco; Zullo, Lodovica; Dal Bello, Maria Giovanna; et al. (Clinical and experimental medicine, 2024)
Keywords: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological - therapeutic use; Biomarkers, Tumor - genetics; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - genetics; Copy number; Disease control; DNA microarrays; Extracellular vesicles; Extracellular Vesicles - genetics; Extracellular Vesicles - metabolism; Female; Hematology; Humans; Immune checkpoint inhibitors; Immune Checkpoint Inhibitors - therapeutic use; Immunotherapy; Internal Medicine; L1 gene; Lung cancer; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Lung Neoplasms - mortality; Lung Neoplasms - pathology; Male; Medicine; Medicine & Public Health; MicroRNAs - blood; MicroRNAs - genetics; Middle Aged; Monoclonal antibodies; Nivolumab - therapeutic use; Non-small cell lung carcinoma; Oncology; Patients; PD-L1 protein; Prognosis; Small cell lung carcinoma; Targeted cancer therapy; Immune checkpoint inhibitor; Nivolumab; Non-small cell lung cancer (NSCLC); Prognosis score; miR-574-5p and miR-181a-5p; Pluripotency of stem cell; Extracellular vesicle miRNA; Toll-like receptor